News Marius Pharmaceuticals Receives PDUFA Date for KYZATREX® NDA for Treatment of HypogonadismMarch 11, 2021Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREXJanuary 27, 2021Marius Pharmaceuticals Submits New Drug Application to U.S. FDA for Next-generation Oral Testosterone Replacement Therapy in Male Patients with HypogonadismJanuary 5, 2021Marius Pharmaceuticals Announces Issuance of Two Key Patents Protecting its Proprietary Oral Testosterone TherapyMay 21, 2020Marius Pharmaceuticals Completes Efficacy Phase 3 StudySeptember 26, 2018
Marius Pharmaceuticals Receives PDUFA Date for KYZATREX® NDA for Treatment of HypogonadismMarch 11, 2021
Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREXJanuary 27, 2021
Marius Pharmaceuticals Submits New Drug Application to U.S. FDA for Next-generation Oral Testosterone Replacement Therapy in Male Patients with HypogonadismJanuary 5, 2021
Marius Pharmaceuticals Announces Issuance of Two Key Patents Protecting its Proprietary Oral Testosterone TherapyMay 21, 2020
